MCA Stability Tool

This compatibility recommendation is derived from One-Alpha 250nanogram capsules (Neon Healthcare Ltd) and Alfacalcidol 250nanogram capsules (Strides Pharma UK Ltd).

Compatible

ActiDol 0.5microgram capsules (MaN Pharma Ltd)

Explore other Alfacalcidol formulations Explore other Alfacalcidol 500nanogram capsules suppliers

Stability Notes

No special precautions for storage.

Provenance

This compatibility recommendation is derived from One-Alpha 500nanogram capsules (Neon Healthcare Ltd).

Compatible

ActiDol 1microgram capsules (MaN Pharma Ltd)

Explore other Alfacalcidol formulations Explore other Alfacalcidol 1microgram capsules suppliers

Stability Notes

No special precautions for storage.

Provenance

This compatibility recommendation is derived from One-Alpha 1microgram capsules (Neon Healthcare Ltd).

No Stability Information

ActiFerr-F 322mg tablets (MaN Pharma Ltd)

Explore other Ferrous fumarate formulations Explore other Ferrous fumarate 322mg tablets suppliers

Stability Notes

There are no stability notes available for this medicine.

Incompatible

ActiFerr-G 300mg tablets (MaN Pharma Ltd)

Explore other Ferrous gluconate formulations Explore other Ferrous gluconate 300mg tablets suppliers

Stability Notes

Store in airtight containers, protect from light. Contains a desiccant, which makes it unsuitable for MCA.

Provenance

This compatibility recommendation is derived from Ferrous gluconate 300mg tablets (Kent Pharma (UK) Ltd).

Use with caution

ActiFerr-S 200mg tablets (MaN Pharma Ltd)

Explore other Ferrous sulfate formulations Explore other Ferrous sulfate 200mg tablets suppliers

Stability Notes

Store in an airtight container, protect from light and moisture.

Provenance

This compatibility recommendation is derived from Ferrous sulfate 200mg tablets (Sandoz Ltd).

No Stability Information

ActiMint 0.2ml gastro-resistant capsules (MaN Pharma Ltd)

Explore other Peppermint formulations Explore other Peppermint oil 0.2ml gastro-resistant capsules suppliers

Stability Notes

There are no stability notes available for this medicine.

Print this list

Compatible

Medicines suitable for use in MCAs, although use is likely to be off-label.  Keep medicines in MCAs for the shortest time necessary. Generally, up to 5 weeks maximum unless otherwise specified, or consider up to 8 weeks if the MCA is airtight (sealed).  Consider the risk to the individual from potency loss or dose variability, particularly with unsealed devices.  Monitor for any changes in therapeutic effect or increased adverse effects after MCA initiation.

Use with caution

There are concerns about stability and/or there is a lack of stability data available. These medicines can theoretically be used in MCAs, although use is likely to be off-label.  Mitigation measures may need to be considered.  Keep medicines in MCAs for the shortest time necessary.  Generally, up to 5 weeks maximum unless otherwise specified, or consider up to 8 weeks if the MCA is airtight (sealed). Consider the risk to the individual from potency loss or dose variability, particularly with unsealed devices. Monitor for any changes in therapeutic effect or increased adverse effects after MCA initiation.

Incompatible

Medicines under this category are not suitable for use in MCAs.

No Stability Information

These medicines have not been reviewed by SPS.